Chelsea Fidai, MD

Dr. Chelsea Fidai, M.D. is a double board-certified dermatologist and Mohs surgeon with a strong foundation in medical, surgical, and cosmetic dermatology. She currently serves as Founder of The Center for Laser and Skin Surgery in Hermosa Beach, California, where she offers advanced expertise in procedures such as Mohs surgery, laser therapy, skin rejuvenation, scar revision, and birthmark treatment. Dr. Fidai is widely recognized for her patient-centered approach and commitment to providing the highest standard of dermatologic care through innovation, precision, and compassion.

Dr. Fidai earned her Doctor of Medicine from Tulane University School of Medicine, where she was inducted into the Alpha Omega Alpha Medical Honor Society for her outstanding academic performance and leadership. In addition, she holds a Master’s Degree in Pharmacology from Tulane University, equipping her with a strong scientific foundation that enhances her understanding of therapeutic and cosmetic treatments. She completed dermatology residency training at Henry Ford Health System, followed by a prestigious post-residency advanced surgical and cosmetic fellowship program with Dr. Roy Geronemus in New York City.

Building on her extensive training and experience, Dr. Fidai is now launching her own practice, The Center for Laser and Skin Surgery, set to open in January. This new center will specialize in advanced dermatologic care, including laser procedures, Mohs surgery, and aesthetic rejuvenation. Through her new practice, Dr. Fidai aims to create a patient experience that blends medical excellence with artistry and compassion—empowering individuals to achieve healthy, radiant skin with confidence.

• Tulane University School of Medicine - MD
• Tulane University School of Medicine - MS
• Tulane University - BS

• Advanced Cardiovascular Life Support

• Alpha Omega Alpha Medical Honors Society

• American Academy of Dermatology (AAD)

Dr. Fidai is a published author in dermatology, with works including “A Clinical and Biological Review of Keratoacanthoma” (The British Journal of Dermatology, 2021) and “Successful Treatment of Facial Port-Wine Birthmark in a Premature Infant” (JAAD Case Reports, 2021).